Alexey TarasovBioMed X Innovation Center
Dr. Alexey Tarasov is currently a research group leader at the BioMed X Innovation Center, Heidelberg, Germany. After graduating in physics from the University of Dusseldorf in 2009, Alexey moved to the University of Basel where he received his PhD for his work on chemical sensing with silicon nanowires in 2012. Thanks to a grant from the Swiss National Science Foundation, Alexey then moved as a postdoctoral research fellow to the Georgia Institute of Technology, Atlanta, GA, where he worked on synthesis and characterization of 2D materials beyond graphene. In 2015, Alexey joined BioMed X to develop a nanomaterial-based biosensor platform for near-patient testing in collaboration with Roche Diagnostics.
演讲题目:Are graphene field-effect transistors ready for point-of-care diagnostics?
主题会场石墨烯在临床医疗领域的应用
开始时间
结束时间
内容摘要
Over the past several decades, there has been a growing need for the detection and quantification of chemical and biological species in different areas, including biomedical research, health care, agriculture, and environmental monitoring. Among available sensor technologies, potentiometric biosensors based on electrolyte-gated field-effect transistors are very promising due to their high sensitivity, rapid electronic readout, and label-free analyte detection [1,2]. However, two major challenges have limited their use in complex physiological samples such as blood or serum: 1) screening of the analyte charge by the background ions and 2) non-specific adsorption [3-5]. In this work, we overcome these challenges by tailoring the graphene sensing surface with short specific biorecognition molecules and a polymer polyethylene glycol, and demonstrate direct detection of proteins with femtomolar detection limit in whole serum [6]. Multi-parametric analysis of the device’s electronic response shows that the mechanism behind this very sensitive detection cannot be explained by a commonly reported electrostatic gating effect. Rather, the observed combination of charge neutrality point (CNP) shifts and asymmetric mobility changes are attributed to the modulation of scattering by charged impurities, which seem to dominate the device’s transfer characteristics. The presented approach is universal, does not require any sample pretreatment, labelling or washing steps, and can enable the next generation of point-of-care devices for diagnostics of human and animal diseases, if the large-scale manufacturing of graphene can be standardized.
[1]A. Tarasov et al., Biosens. Bioelectron. 79, 669 (2016)
[2]A. Tarasov et al., 2D Materials 2, 044008 (2015)
[3]A. Zhang and C.M. Lieber, Chem. Rev. 116, 215 (2016)
[4]O. Gutierrez-Sanz et al. ACS Sensors 2, 1278 (2017)
[5]M. Filipiak et al., Sens. Actuators B: Chem. 255, 1507 (2018)
[6]N. Andoy et al., Adv. Mater. Technol., in revision